 MINNEAPOLIS, July 21, 2021 GLOBE NEWSWIRE -- CVRx, Inc. CVRx, a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial 833 730-3980 for U.S. callers, or 1 720 405-2140 for international callers, approximately ten minutes prior to the start time and reference conference code 1659235. To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.cominvestor-relations. The webcast replay will be available on the CVRx website for 12 months following completion of the call. About CVRx, Inc. CVRx is focused on the development and commercialization of BarostimTM, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the bodys baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the US. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Investor Contact: Mark Klausner or Mike VallieWestwicke, an ICR Company Media Contact: Lisa Murray Trevi Communications, Inc.978.750.0333 617.835.0396 